Literature DB >> 9459158

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection.

L Biassoni1, M Granowska, M J Carroll, S J Mather, R Howell, D Ellison, F A MacNeill, C A Wells, R Carpenter, K E Britton.   

Abstract

The extent of primary surgery for breast cancer could be tailored to the patient if previous information on the presence or absence of lymph node involvement could be reliably determined. Prospective radioimmunoscintigraphy in 29 patients with primary breast cancer that was found on screening has been undertaken with 555 MBq (15 mCi) 99mTc SM3, an Imperial Cancer Research Fund (ICRF) murine monoclonal antibody, 0.5 mg with images at 10 min and 22 h, and analysis using a change detection algorithm. Sites of significant change between the early and later images were displayed as a map of probabilities. Image-positive and -negative axillary lymph nodes were compared by histology in the 28 evaluable patients. The correct identification of the presence or absence of node involvement, even if impalpable, has been shown in 24 out of 28 patients (29 lymph node groups). Sensitivity was 90% (nine out of ten), specificity 84% (16 out of 19) and accuracy 86%. These results encourage further assessment of this technique.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459158      PMCID: PMC2151258          DOI: 10.1038/bjc.1998.21

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody.

Authors:  L F Massuger; P Kenemans; R A Claessens; R H Verheijen; C P Schijf; S P Strijk; L G Poels; R G van Hoesel; F H Corstens
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

2.  Reduction-mediated technetium-99m labeling of monoclonal antibodies.

Authors:  S J Mather; D Ellison
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

3.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

Authors:  J Burchell; S Gendler; J Taylor-Papadimitriou; A Girling; A Lewis; R Millis; D Lamport
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Detection of primary colorectal cancer with indium 111 monoclonal antibody B72.3.

Authors:  R J Doerr; H Abdel-Nabi; J M Baker; S Steinberg
Journal:  Arch Surg       Date:  1990-12

5.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas.

Authors:  A Girling; J Bartkova; J Burchell; S Gendler; C Gillett; J Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

6.  Patients with early breast cancer benefit from effective axillary treatment.

Authors:  J R Harris; R T Osteen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake.

Authors:  M Granowska; J R Jass; K E Britton; J M Northover
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

8.  Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer.

Authors:  J J Tjandra; I S Russell; J P Collins; J T Andrews; M Lichtenstein; D Binns; I F McKenzie
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

9.  Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study.

Authors:  A Bischof-Delaloye; B Delaloye; F Buchegger; W Gilgien; A Studer; S Curchod; J C Givel; F Mosimann; J Pettavel; J P Mach
Journal:  J Nucl Med       Date:  1989-10       Impact factor: 10.057

10.  Radiolabelled stripped mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian tumours.

Authors:  M Granowska; S J Mather; T Jobling; M Naeem; J Burchell; J Taylor-Papadimitriou; J Shepherd; K E Britton
Journal:  Int J Biol Markers       Date:  1990 Apr-Jun       Impact factor: 3.248

View more
  6 in total

1.  A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.

Authors:  Paula Henderikx; Nicole Coolen-van Neer; Anita Jacobs; Edith van der Linden; Jan-Willem Arends; Jürgen Müllberg; Hennie R Hoogenboom
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 2.  Recent trends in antibody-based oncologic imaging.

Authors:  Sukhwinder Kaur; Ganesh Venktaraman; Maneesh Jain; Shantibhusan Senapati; Pradeep K Garg; Surinder K Batra
Journal:  Cancer Lett       Date:  2011-10-20       Impact factor: 8.679

Review 3.  MUC1 and the immunobiology of cancer.

Authors:  Joyce Taylor-Papadimitriou; Joy M Burchell; Timothy Plunkett; Rosalind Graham; Isabel Correa; David Miles; Michael Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.698

4.  Immunolymphoscintigraphy for metastatic sentinel nodes: test of a model.

Authors:  A H Chakera; B S Nielsen; J Madsen; J Romer; P E G Kristjansen; I Buch; T Binderup; C Ingvar; A Nalla; A Kjaer; B Hesse
Journal:  Int J Mol Imaging       Date:  2011-04-28

5.  Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1.

Authors:  A R Al-Yasi; M J Carroll; D Ellison; M Granowska; S J Mather; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

Review 6.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.